Lifeward Ltd. logo

Lifeward Ltd.(LFWD)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$4.06
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for LFWD

11/13/2026: LFWD (1-star) is currently NOT-A-BUY. Pass it for now.

Lifeward Ltd. is a medical device company specializing in wearable exoskeletons and physical rehabilitation technologies like AlterG anti-gravity systems. The company features a recognized market position and established Medicare reimbursement pathways that support patient adoption across clinical and home settings. Its primary growth story centers on expanding its product pipeline and scaling reimbursement coverage globally. However, the company faces ongoing financial losses, execution risks, and competitive pressures typical of micro-cap medical device developers. Lifeward represents a speculative growth opportunity best suited for risk-tolerant investors monitoring clinical execution, cash burn, and reimbursement expansion.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitLifeward offers innovative medical technology growth drivers, but its small scale and early profitability stage present execution risks.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp tactical movements tied to clinical updates or reimbursement news when technical momentum turns positive.
Value investorWeak fitThe company lacks current earnings and positive free cash flows, making traditional value metrics unappealing.
Dividend investorWeak fitLifeward does not pay dividends, focusing entirely on growth and commercial expansion.
Low-risk investorWeak fitHigh share price volatility and micro-cap status expose low-risk investors to substantial downside risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap medical device stocks frequently experience wide price swings based on minor operational updates.
Valuation riskMedium / highValuation relies heavily on long-term adoption assumptions rather than near-term earnings power.
Competition risk (specialized medical robotics competition)Medium / highThe company competes with well-funded competitors in developing advanced rehabilitation tech.
Business qualityMediumLifeward possesses strong proprietary products, but sustained financial self-sufficiency remains a work in progress.
Dividend incomeLow / noneNo dividend is paid to investors.
Execution riskHighSuccessfully scaling global reimbursement and commercial sales execution is critical to financial viability.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 11.53M USD
Price to earnings Ratio -
1Y Target Price 20
Price to earnings Ratio -
1Y Target Price 20
Volume (30-day avg) 17.2K shares
Beta 0.56
52 Weeks Range 3.81 - 9.61
Updated Date 11/15/2026
52 Weeks Range 3.81 - 9.61
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -15.73

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -55.62%
Avg. Invested days 17
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
LFWD receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
LFWD has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, solid earnings growth (+31.2%) is partially offset by weak cash generation (FCF margin -76.4%), negative revenue growth (-14.1%), weak profitability (net margin -90.4%).

Financial Health Rating

★★★★★
LFWD's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 16.5%). Operating efficiency is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is LFWD's strongest growth driver at +31.2% FY2025 versus FY2024 (solid, 4 stars). By comparison, free-cash-flow growth (+22.5%, solid) is also solid, while revenue growth (-14.1%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 1.4% and approximately 55.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 47.06% supports management-shareholder alignment.

Top 5 Institutional Investors

Citadel Advisors Llc 0.64%
Renaissance Technologies Corp 0.38%
UBS Group AG 0.08%
Morgan Stanley - Brokerage Accounts 0.01%
SBI Securities Co Ltd 0.01%

Unit Economics (Per $1K Revenue)

★★★★★
LFWD generates approximately $382 of gross profit, $-767 of operating income, and $-764 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.28%

Quantitative Style Profile

★★★★★
LFWD has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Exoskeleton ProductsReWalk Personal and Rehabilitation exoskeleton systems sold to institutions and qualified individual users.Core high-ticket robotic devices that restore walking capabilities for spinal cord injury patients.
Rehabilitation & Wellness DevicesAlterG anti-gravity treadmills, ReStore exo-suits, and MyoCycle FES systems.Therapy equipment sold primarily to clinics and athletic centers to assist broader physical recovery.
Geographic Exposure (United States & International)Direct and distributor-led sales spanning the United States, Germany, Europe, and Asia-Pacific.The United States serves as the primary revenue driver, supplemented by key European markets like Germany.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 9.07M
Price to Sales(TTM) 0.53
Enterprise Value 9.07M
Price to Sales(TTM) 0.53
Enterprise Value to Revenue 0.42
Enterprise Value to EBITDA 1.04
Shares Outstanding 2.84M
Shares Floating 1.57M
Shares Outstanding 2.84M
Shares Floating 1.57M
Percent Insiders 47.06
Percent Institutions 1.37

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.